COARTEM: Does Artemether or Lumefantrine Kill Malaria and Babesia?
Research review of the two active drugs, their mechanisms, and the evidence in humans and laboratory studies
Coartem contains two drugs:
- Artemether — a semisynthetic derivative of artemisinin, originally obtained from Artemisia annua (sweet wormwood).
- Lumefantrine — a fully synthetic antimalarial drug, also called benflumetol.
The central conclusion: Both components have established antimalarial activity against Plasmodium, and their combination is an effective treatment for susceptible uncomplicated malaria. Artemisinin derivatives also have experimental activity against Babesia, but the evidence for lumefantrine against Babesia is much less developed. Coartem is not an established or FDA-approved treatment for human babesiosis.
1. Comparison of the two drugs
| Research question | Artemether | Lumefantrine |
|---|---|---|
| Origin | Semisynthetic artemisinin derivative | Fully synthetic |
| Kills malaria parasites? | Yes, rapid parasiticidal activity | Yes, slower and longer-lasting activity |
| Main target | Blood-stage Plasmodium | Blood-stage Plasmodium |
| Main mechanism | Endoperoxide activation, radical-mediated parasite injury | Interference with heme detoxification, proposed principal mechanism |
| Kills Babesia in laboratory studies? | Artemisinin-class activity demonstrated; direct evidence varies by species and compound | Direct evidence limited |
| Proven to cure human babesiosis? | No | No |
| Role in Coartem | Rapid reduction of parasite burden | Longer-lasting elimination of remaining susceptible malaria parasites |
The distinction between activity in a test tube, activity in infected animals, and a demonstrated human cure is particularly important for Babesia.
2. Artemether: research on malaria and Babesia
A. Malaria — strong clinical evidence
Artemether is converted to dihydroartemisinin (DHA), an active metabolite.
Its endoperoxide bridge is essential for antimalarial activity. Activation within the parasite produces reactive intermediates that damage important parasite proteins and cellular structures.
Artemether has rapid activity against blood-stage malaria parasites, including P. falciparum.
Its limitation is its short elimination half-life, approximately 1.6–2.2 hours in the FDA pharmacokinetic data. This helps explain why it is combined with a longer-acting partner rather than used alone.
DailyMed+1
B. Babesia — direct laboratory evidence
A particularly important study examined artemether, artemisinin, and lumefantrine against Babesia gibsoni, a parasite that infects dogs.
The investigators found that:
- Artemisinin and artemether inhibited B. gibsoni growth in vitro.
- Atovaquone-resistant B. gibsoni was less susceptible to artemisinin and artemether than wild-type parasites.
- Artemether and lumefantrine showed synergistic activity when combined.
This is direct experimental support for the two Coartem components acting together against a Babesia species. However, it does not establish eradication in animals or efficacy in human B. microti or B. duncani infections.
PubMed
3. Lumefantrine: research on malaria and Babesia
A. Malaria — established effectiveness
Lumefantrine is a synthetic fluorene derivative.
Its proposed principal action is disruption of the malaria parasite’s ability to detoxify heme, including inhibition of β-hematin formation. The exact mechanism is not completely established.
Lumefantrine remains in the circulation much longer than artemether. In the FDA data, its elimination half-life was approximately 101–119 hours in the specified healthy-volunteer studies.
This provides sustained antimalarial exposure after the artemether concentration has declined.
DailyMed
B. Babesia — important direct evidence
The B. gibsoni study is especially relevant because it evaluated lumefantrine in the same experimental system as artemether.
It supports the possibility that the combination may be more active than expected from either agent alone against that organism.
However, synergy against B. gibsoni in vitro is not proof of synergy against B. microti in humans.
The parasites differ biologically, and drug concentrations achievable in human blood must be considered before laboratory findings can be translated into treatment.
4. What does the combination actually prove?
| Organism | Evidence for Coartem or its components | Interpretation |
|---|---|---|
| Plasmodium falciparum | Human clinical trials and regulatory approval | Established effective treatment for susceptible uncomplicated malaria |
| Plasmodium vivax | Blood-stage antimalarial activity | Does not eradicate dormant liver hypnozoites |
| Babesia gibsoni | Direct in-vitro experiments with both components | Growth inhibition and combination synergy demonstrated |
| Babesia microti | Insufficient direct clinical evidence for Coartem | Human cure not established |
| Babesia duncani | Insufficient direct clinical evidence | Human cure not established |
| Babesia divergens | Insufficient direct clinical evidence | Human cure not established |
A significant research question: Could artemether plus lumefantrine have useful activity against atovaquone-resistant Babesia?
The B. gibsoni study makes this a reasonable subject for further investigation, but its observation of reduced susceptibility in resistant parasites also cautions against assuming that Coartem reliably overcomes atovaquone resistance.
5. Human malaria studies: how effective is Coartem?
Pooled analysis of 61 studies, 14,327 patients
97.6%
Day-28 PCR-adjusted therapeutic efficacy
96.0%
Day-42 PCR-adjusted therapeutic efficacy
These are malaria results, not Babesia cure rates.
PubMed
A separate pooled analysis of seven clinical studies reported day-28 PCR-corrected parasitological cure rates of 97.1% in evaluable adults and 97.3% in evaluable children.
PubMed
One important 2026 update: the CDC now recommends a five-day artemether-lumefantrine course for uncomplicated P. falciparum malaria, rather than the older three-day regimen, in its U.S. clinical guidance. This malaria recommendation should not be extrapolated to babesiosis.
CDC+1
6. Clinical limitations and safety
The CDC continues to recommend atovaquone plus azithromycin as the preferred treatment for symptomatic babesiosis, with clindamycin plus quinine as an alternative. Prolonged treatment and parasite monitoring may be necessary in highly immunocompromised patients.
CDC
Coartem also requires attention to QT prolongation, interacting QT-prolonging drugs, strong CYP3A4 inducers, and food-dependent absorption. These are particularly relevant when considering combinations with other antimicrobial agents.
Access Data
7. Full references and research sources
1. Novartis Pharmaceuticals Corporation. COARTEM (artemether and lumefantrine) tablets: Full Prescribing Information. DailyMed, U.S. National Library of Medicine. Label updated March 26, 2026. Official prescribing information (opens in new tab)
2. The efficacy of artemisinin, artemether, and lumefantrine against Babesia gibsoni in vitro. Veterinary Parasitology, 2015. PMID: 25523292. PubMed study (opens in new tab). The key direct Babesia study.
3. WorldWide Antimalarial Resistance Network. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. The Lancet Infectious Diseases. 2015. PMID: 25788162. PubMed study (opens in new tab)
4. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. American Journal of Tropical Medicine and Hygiene. 2011. PMID: 22049029. PubMed study (opens in new tab)
5. Mueller EA, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Tropica. 2006;100:41–53. DOI: 10.1016/j.actatropica.2006.09.007. PubMed study (opens in new tab)
6. Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database of Systematic Reviews. 2005. PMID: 16235412. Cochrane review (opens in new tab)
7. The clinical efficacy of artemether/lumefantrine (Coartem). Malaria Journal. 2009. PMID: 19818172. PMCID: PMC2760240. PubMed review (opens in new tab)
8. Centers for Disease Control and Prevention. Treatment of Uncomplicated Malaria. Updated August 17, 2026. CDC clinical guidance (opens in new tab)
9. Centers for Disease Control and Prevention. Clinical Care of Babesiosis. February 13, 2024. CDC babesiosis treatment guidance (opens in new tab)
10. Artemether for severe malaria. Cochrane Database of Systematic Reviews. 2019. PMID: 31210357. PubMed review (opens in new tab)
References 2–7 and 10 are identified by their indexed publication titles and PubMed records; they are not a complete author-by-author bibliography.
Final research conclusions
Malaria: Artemether and lumefantrine are both effective antimalarial agents, with strong clinical evidence for the combination.
Babesia: The most directly relevant experiment demonstrates growth inhibition and synergy against B. gibsoni in vitro. This is meaningful preliminary evidence for both components, not merely for the artemisinin family.
Unanswered question: Whether the same combination can achieve sustained parasitological clearance of human B. microti, B. duncani, or B. divergens infections remains unproven. Controlled species-specific susceptibility, pharmacokinetic, animal, and human studies are needed.